Braeburn Pharmaceuticals

Braeburn Pharmaceuticals

  • Founded: 2012
  • Location: Plymouth Meeting, PA
  • Employee range: 11 - 50
  • Clinical stage: COM
  • Therapy area: Opioid use disorder
  • Drug types: ABU
  • Lead product: Brixadi
  • Product link:
  • Funding: $100M Jan 2018

job board

Short description:

Out licensing

Drug notes:

Contact us to add description:

Long description:

Braeburn is developing drugs to fight against opioid addiction. Opioid overdose and misuse are a significant public health crisis in the US today affecting 2 million people. To treat opioid addiction, Braeburn is developing a FluidCrystal® injection depot technology, a next generation delivery system that includes a lipid-based liquid with a dissolved active ingredient. Braeburn is adapting this technology to deliver buprenorphine, a medication that normalizes brain chemistry and blocks the euphoric effects of opioids relieving physiological cravings without negative effects. The extended-release injected therapy of buprenorphine for weekly and monthly subcutaneous injections for moderate to severe opioid use disorder was recently accepted by the FDA.


Braeburn Pharmaceuticals
Associate Director of Training
Hybrid/ Remote|11 days ago
Braeburn Pharmaceuticals
Key Account Manager - Los Angeles, CA
Remote - Los Angeles, CA|19 days ago
Braeburn Pharmaceuticals
Key Account Manager - Chicago, IL South
Remote - Chicago, IL South|26 days ago
Braeburn Pharmaceuticals
Medical Science Liaison - Southeast
Remote|33 days ago
Braeburn Pharmaceuticals
Manager, Sales Operations
Remote - Plymouth Meeting, PA|39 days ago
Braeburn Pharmaceuticals
Pricing and Contracting Manager
Plymouth Meeting, PA|80 days ago
Braeburn Pharmaceuticals
Director of Trade
Plymouth Meeting, PA|80 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy